Generation of a Nonbilayer Lipid Nanoenvironment after Epitope Binding Potentiates Neutralizing HIV-1 MPER Antibody.

Johana Torralba, Akio Ojida, Jose M M Caaveiro, Edurne Rujas, Sara Insausti, José L Nieva, Carmen Domene, Ander Ramos-Caballero, Brian Wiley, Saul González-Resines, Anne Elizaga-Lara, Christine Shamblin, Michael B Zwick

Journal: ACS applied materials & interfaces 2024;16(44):59934-59948

PMID: 39446590

Abstract

Establishment of interactions with the envelope lipids is a cardinal feature of broadly neutralizing antibodies (bnAbs) that recognize the Env membrane-proximal external region (MPER) of HIV. The lipid envelope constitutes a relevant component of the full "quinary" MPER epitope, and thus antibodies may be optimized through engineering their capacity to interact with lipids. However, the role of the chemically complex lipid nanoenvironment in the mechanism of MPER molecular recognition and viral neutralization remains poorly understood. To approach this issue, we computationally and experimentally investigated lipid interactions of broadly neutralizing antibody 10E8 and optimized versions engineered to enhance their epitope and membrane affinity by grafting bulky aromatic compounds. Our data revealed a correlation between neutralization potency and the establishment of favorable interactions with small headgroup lipids cholesterol and phosphatidylethanolamine, evolving after specific engagement with MPER. Molecular dynamics simulations of chemically modified Fabs in complex with an MPER-Transmembrane Domain helix supported the generation of a nanoenvironment causing localized deformation of the thick, rigid viral membrane and identified sphingomyelin preferentially occupying a phospholipid-binding site of 10E8. Together, these interactions appear to facilitate insertion of the Fabs through their engagement with the MPER epitope. These findings implicate individual lipid molecules in the neutralization function of MPER bnAbs, validate targeted chemical modification as a method to optimize MPER antibodies, and suggest pathways for MPER peptide-liposome vaccine development.

Address: Instituto Biofisika (CSIC, UPV/EHU), University of the Basque Country (UPV/EHU), P.O. Box 644, Bilbao 48080, Spain.; Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), P.O. Box 644, Bilbao 48080, Spain.; Instituto Biofisika (CSIC, UPV/EHU), University of the Basque Country (UPV/EHU), P.O. Box 644, Bilbao 48080, Spain.; Department of Chemistry, University of Bath, Claverton Down, Bath BA2 7AX, United Kingdom.; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California 92037, United States.; Department of Chemical Biology, School of Pharmaceutical Sciences, Kyushu University, Fukuoka 819-0395, Japan.; Laboratory of Protein Drug Discovery, School of Pharmaceutical Sciences, Kyushu University, Fukuoka 819-0395, Japan.; Instituto Biofisika (CSIC, UPV/EHU), University of the Basque Country (UPV/EHU), P.O. Box 644, Bilbao 48080, Spain.; Department of Pharmacy and Food Sciences, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria 01006, Spain.; Basque Foundation for Science, Ikerbasque, Bilbao48013, Spain.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.